Angioimmunoblastic Lymphadenopathy With Dysproteinemia - 29 Studies Found

Completed : A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
: Untreated T-cell Angioimmunoblastic Lymphoma
: 2005-09-12
:
  • Drug: Rituximab 375 mg/m2 D1
Completed : Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
: Lymphoma
: 2009-08-12
:
  • Drug: cyclophosphamide
  • Drug: fludarabine p
Terminated : Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
: Lymphoma
: 2003-10-03
: Drug: cyclosporine Cyclosporine doses will be based on actual body weight unless actual body weight is &
Recruiting : Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
:
  • Follicular Variant Peripheral T-Cell Lymphoma
  • Recurrent Angioimmunobla
    : 2015-08-10
    :
    • Biological: Anti-ICOS Monoclonal Antibody MEDI-570

Completed : Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
:
  • Solid Tumor
  • Glioma
  • Angioimmunoblasti
    : 2014-10-16
    : Drug: AG-221 AG-221 administered orally on every day of 28 day cycles until disease progression or unacc
Completed : A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
: Lymphoma
: 2017-01-16
: Drug: plitidepsin Other Name: APLD Aplidine
Completed : Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
: T-cell Lymphoma
: 2012-01-20
: Drug: Lenalidomide Lenalidomide
Completed : Risk Stratification of Nodal PTCL
:
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic
    : 2017-01-31
Completed : Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
:
  • Peripheral T Cell Lymphoma, Unspecified
  • Angioimmunoblastic Lymphadenop
    : 2008-07-25
    :
    • Biological: alemtuzumab Additi
Completed : CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
:
  • Peripheral T-cell Lymphoma NOS
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • Drug: Cyclophosphamide 750mg/m
Next >>>